Strategic performance report underscores Global Fund successes but challenges remain for service delivery and coverage of key populations
The Global Fund has achieved its targets in resource mobilization (i.e. Fifth Replenishment) and in aligning its investments with country needs and national strategic plans.
This information is contained in a report on Strategic Performance Reporting prepared for the Board’s 40th meeting just completed in Geneva on 14-15 November.
Results for the Global Fund partnership in 2017 reveal large increases in lives saved and people treated for HIV, TB and malaria
The Global Fund has released its Results Report 2018, the first such report to use the revised methodology adopted by the Fund for tracking and reporting impact and results. The Results Report 2018 provides results for the year 2017.
Mainland Tanzania submitted a funding request for its HIV and TB components that resulted in the Global Fund Board approving three grants, including a TB/HIV grant to a civil society principal recipient (PR) –– AMREF Health Africa. The Ministry of Finance and Planning (MOFP) was awarded an HIV grant and a TB grant.
Mozambique’s TB/HIV funding request to the Global Fund builds on achievements of current grants, TRP says
Among the grants approved by the Board in the third batch of funding (see GFO article) were four TB/HIV grants to Mozambique. In this article, we report on the comments of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC) on the funding request from which these grants emanated.
Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says
In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation
Global Fund expresses concern over Benin’s plan to shift funds away from HIV and malaria towards an RSSH funding request
When it reviewed the funding requests from Benin, the Grant Approvals Committee (GAC) and the Technical Review Panel (TRP) expressed serious concerns about what they perceived as gaps in Benin’s HIV and malaria programs – which, they said, were partly due to the decision of the country coordinating mechanism (CCM) to shift some of its allocation towards an RSSH funding request.
The original allocation for Benin was as follows:
A new database is being developed in Eastern Europe and Central Asia (EECA) containing information on antiretrovirals (ARVs) in use in 15 countries: Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Poland, the Russian Federation, Tajikistan, Ukraine and Uzbekistan.
In the first half of 2016, through programs supported by the Global Fund, another 787,000 people were put on antiretroviral treatment (ART) for HIV, bringing the total to date to 10 million, a 9% increase over end-2015 results and a 17% increase over the number a year ago. Three countries account for 77% of the increase from six months ago: Kenya (52%), Tanzania (16%) and Mozambique (9%).
In July 2016, the Global Fund Board approved $388 million in funding for six shortened grants to allow them to continue to provide services from the original end date of their grants to the end of 2017. Of the $388 million, $383 million is new funding. It comes from the $700 million that the Finance and Operational Performance Committee said in March 2016 was available for portfolio optimization.